SlideShare a Scribd company logo
1 of 46
Bad Air
Thomas Holland
October 25, 2007
“What is the most repeated failure in all
of global health? It could well be the
commitment to eradicate malaria.”
Bill Gates, October 17,2007
45 minutes from now you
will know all of this:
 Malaria epidemiology
 A historical perspective on malaria
 Some romantic malaria-themed poetry to
use on your next date
 Clinical manifestations and diagnosis
 Basics of treatment
 Malaria at DUMC
 Global eradication efforts
 Why the VA Jets will win the Turkey Bowl
this year
What is malaria?
 Malaria is a vector-borne disease
caused by protozoa:
– P. falciparum
– P. vivax
– P. ovale
– P. malariae
– P. knowlesi
Worldwide Distribution
SI Hay, CA Guerra, AJ Tatem, AM Noor and RW Snow, The global
distribution and population at risk of malaria: past, present and future,
Lancet Infect Dis 4 (2004), pp. 327–336.
Worldwide distribution
http://en.wikipedia.org/wiki/Malaria
Malaria Epidemiology
 300-500 million cases per year
worldwide
 700,000 to 2.7 million deaths per year
 ~1300 cases in the US reported to the
CDC in 2004
 Average 2 cases per year at DUMC
Malaria in Antiquity
 Genetic analysis has suggested that a virulent
Plasmodia falciparum evolved 6000 years ago
(“Malaria’s Eve”) around the time of the emergence
of agricultural societies
 However it appears that some populations are
50,000 to 400,000 years old  ie, older than homo
sapiens
 
Malaria in antiquity
 Enlarged spleen,
periodic fevers,
headaches, and
chills are described
in the Ebers
papyrus (~1550
BC) as well as in
ancient Chinese
medical texts
www.wikipedia.org
Nobel Prizes for work on
malaria
 1902 – Ronald Ross
 1907 – Charles Louis Alphonse Laveran
– discovered that malaria is caused by a protozoan
 1927 – Julius Wagner-Juaregg
– for his discovery of the therapeutic value of malaria
inoculation in the treatment of dementia paralytica
(caused by neurosyphilis)
 1948 - Paul Hermann Müller
– For his discovery of the high efficiency of DDT as a contact
poison against several arthropods
Ronald Ross
 Scottish physician,
mathematician, poet, playwright,
writer, and painter
 Bombay 1895 – recruited
volunteers to drink water with
dead mosquitoes  caused fever
but not parasitemia
 Switched tactics to having
mosquitoes bite infected patients
then dissecting the mosquitoes,
but was using Culex and Aedes
instead of Anopheles until 1897
http://en.wikipedia.org/wiki/Ronald_ross
This day relenting God
Hath placed within my hand
A wondrous thing: and God
Be praised. At his command
Seeking his secret deeds
With tears and toiling breath,
I find thy cunning seeds
O million-murdering death
I know this little thing
A myriad men will save.
O death, where is thy sting?
Thy victory, O grave?
http://www.utdol.com
Clinical Manifestations
 FEVER
 HA, myalgia, N/V/D, abdominal pain, cough,
diarrhea
 Anemia, thrombocytopenia, splenomegaly,
jaundice
– hepatomegaly uncommon
 Cerebral malaria with P. falciparum
– AMS, seizures, coma
– more common in kids
Diagnosis
 In Malawi: mother’s report of fever in her child –
93% sensitive, 21% specific
 Missionary algorithm: fever and/or diarrhea  treat
for malaria for three days  if no better, treat for
typhoid for three days  if no better, think
 T>37.6 + nail pallor + splenomegaly – 85%
sensitive, 41% specific
 Thick/thin smear – remains the standard
Diagnosis
 Thick smear: one drop of blood on a
slide, spread to area 1cm2
– RBCs hemolyzed, parasites and
leukocytes detectable
– Used to detect and quantify parasitemia
 Thin smear: fixed with methanol  no
hemolysis
– Used to identify species
www.cdc.gov www.utdol.com
Malaria at DUMC
 Consider malaria in any febrile patient who
has been to a malaria-endemic area in the
year prior to presentation
– In the 2007 JAMA review, 98% of patients with
P. falciparum in the US became symptomatic
within 3 months of arrival to the US
– 96% of patients with non-falciparum malaria
became symptomatic within 12 months
Malaria drugs
 Quinoline derivatives – inhibit heme polymerase 
accumulate free heme which is toxic to the
parasites
– chloroquine, quinine, quinidine, amodiaquine, mefloquine,
halofantrine, primaquine
 Artemisinin derivatives – bind iron in malarial
pigment  form free radicals toxic to the parasites
– Artemisinin, artemether, artesunate
– Not available in the US
– Clinical resistance has not been documented
Malaria drugs (cont.)
 Antifolates – pyrimethamine, sulfonamides,
dapsone, proguanil
 Antimicrobials – clindamycin, atovaquone,
tetracyclines
– synergistic with quinolines
– active against blood schizonts
Global Eradication Efforts
 WHO in 1955 set a goal to eradicate malaria
 The US was heavily invested, behind the support
of Eisenhower, George Marshall, and JFK
"I propose that the United States join with other
nations and organizations which are already
spending over $50 million a year on anti-
malaria activities. In five years, these
activities are expected to eradicate this
disease."
- Eisenhower, addressing Congress in 1953
Global Eradication Efforts
– The First Attempt
 Efforts were largely based on DDT and
chloroquine, which was successful for a time
– But insecticide-resistant mosquitoes evolved,
and chloroquine-resistant parasites
– And there was that issue with fragile eggshells
 Funding decreased after the failure of the
campaign in the 1950’s and 1960’s
Global Eradication Efforts
– The Resurgence
 The Global Fund to Fight AIDS,
Tuberculosis and Malaria (GFATM)
– an independent public-private partnership
formed in 2002
– was first proposed by the UN Secretary-
General, Kofi Annan
– Approx 1/3 of the money is donated by
the US
Global Eradication Efforts
– The Resurgence
 President’s Malaria Initiative (2005)
– Pledge to increase funding by the US by
at least $1.2 billion over five years
– Joins USAID, DHHS, CDC, Dept of State
– Goal is to provide prevention and
treatment measures to 85% of children
under 5 and pregnant women
Global Eradication Efforts
– The Resurgence
 Roll Back Malaria Partnership
– Formed in 1998 by WHO, UNICEF, UNDP, World
Bank
– Aims for coverage of:
 60% of children and pregnant women with ITNs
 60% of malaria cases receive effective therapy within
24 hours
 60% of pregnant women receive intermittent
presumptive therapy
 60% of epidemics be detected within two weeks of
onset and responded to within 2 more weeks
Global Eradication Efforts
– The Resurgence
 World Bank’s “Rolling Back Malaria:
The Global Strategy and Booster
Program“
– Emphasizes the economic cost of malaria
(close to 1% of sub-Saharan Africa’s
GDP) and the cost-effectiveness of
control (eg $2,762 per life saved for a
program in Brazil)
http://siteresources.worldbank.org/INTMALARIA/Resources/377501-
1114188195065/execsum.pdf
Global Eradication Efforts
 WHO in 2005 asked members to set a target
of 50% reduction in malaria burden by 2010
and 75% by 2015
 Melinda Gates, October 17, 2007:
“… the rising concern of people around the world
represents an historic opportunity not just to
treat malaria or to control it—but to chart a long-
term course to eradicate it.”
 Bill and Melinda Gates Foundation
– $7.8 billion in grants dispersed from
inception to March 2007 (not all for
malaria)
– Projects have included:
 successful ITN coverage in Zambia
 funding the RTS/S vaccine trial in
Mozambique
 Current funding is about $2 billion per
year
– $1 billion donor money
– $600 million from endemic countries and
their citizens
– $400 million R&D
 2006 Sports Illustrated column established a
program to distribute insecticide-treated
nets (nothingbutnets.com)
 “I teach you to lie, cheat, and
steal, and as soon as my back
is turned you wait in line? Get
an MRI and get a better
medical history”
 “If a human being had actually
looked at his blood, anywhere
along the way, instead of just
running tests through the
computer, parasites would
have jumped right out at
them.“
 “Patients sometimes get better.
You have no idea why, but
unless you give a reason they
won't pay you.”
http://economist.com/world/interna
tional/displaystory.cfm?story_id=96
16897
The Backlash
The Backlash
“Chronic disease is already the biggest
problem for poor and middle-income
countries. To concentrate so much on
infections is to add to the health
burden of the next generation in what
are already the world's poorest,
unhealthiest places.”
-The Economist, 8/9/07
Strategies For Malaria Control
 Vector control
– eg. insecticides
 Exposure prophylaxis
– eg. bednets
 Clinical management
– better drugs, better access
 Vaccines
Malaria vaccine
 Basic reproductive number R0 for an infection 
– R0 = mean # of new cases a single infected case will
cause in a population with no immunity and in the
absence of interventions to control the infection
 If R0 < 1 then the infection will not persist in a
population
 R0 > 1 then epidemics can occur
 1 – 1/R0 is the proportion of the population that
needs to be vaccinated to provide herd immunity
(prevent sustained spread)
Herd Immunity Thresholds for Selected
Vaccine-Preventable Diseases
Immunization Levels
Disease Ro Herd
Immunity
1999
19-35
Months
1997-1998
Pre-School
Diphtheria 6-7 85%* 83%* 9%
Measles 12-18 83-94% 92% 96%
Mumps 4-7 75-86% 92% 97%
Pertussis 12-17 92-94% 83%* 97%
Polio 5-7 80-86% 90% 97%
Rubella 6-7 83-85% 92% 97%
Smallpox 5-7 80-85% __ __
*4 doses
† Modified from Epid Rev 1993;15: 265-302, Am J Prev Med 2001; 20 (4S):
88-153, MMWR 2000; 49 (SS-9); 27-38
 The R0 for malaria in Africa is
estimated at 50-100
 Therefore to eliminate endemic
malaria would require 99% coverage
with a lifelong vaccine (that is 100%
effective) at 3 months of age
Malaria Vaccine
 The first human malaria vaccine was
reported in 1973 – but used the bites of
thousands of mosquitoes infected with
irradiated plasmodia
 Current efforts have two broad strategies
– subunit vaccines that mimic naturally acquired
immunity
– experimental model vaccines, eg live attenuated
parasites and transmission-blocking antigens
Malaria Vaccine
 SPf66 was the first vaccine to undergo field
trials after promising phase I trials, but was
not more effective than placebo in larger
trials
 There are currently at least 25 candidate
vaccines in development, of which
RTS,S/AS02A is the furthest along
Malaria Vaccine
 Double-blind RCT of 214 children in Mozambique
who received RTS,S/AS02D or Hep B vaccine at 10
weeks, 14 weeks, and 18 weeks of age
 Vaccine is made of 2 falciparum surface proteins
(RTS and S fused to HbsAg)
 Primary endpoint was safety at 6 months
 Secondary endpoint was vaccine efficacy at 3
months – which was 65% (5% of children who got
the malaria vaccine vs 8% of the controls)
Summary
 Consider malaria in any febrile patient with
recent travel to an endemic area
 Get a thick and thin smear
 Poetry about malaria is actually not very
romantic
 Although the malaria epidemic continues
largely unabated, there is growing political
and financial will to push for eradication
“ I hope you will judge yourselves not on your
professional accomplishments alone, but
also on how well you have addressed the
world’s deepest inequities… on how well you
treated people a world away who have
nothing in common with you but their
humanity.”
- Bill Gates
June 7, 2007
References
 Joy DA, Feng X, et al. Early Origin and recent expansion of Plasmodium falciparum. Science; 2003 Apr
11;300(5617):318-21.
 Singh B, Kim Sung L, et al. A large focus of naturally acquired Plasmodium knowlesi infections in
human beings. Lancet 2004 Mar 27;363(9414):1017-24.
 Anderson RM, May RM. "Population biology of infectious diseases: Part I". Nature 280 (5721): 361-7.
 CDC: http://www.bt.cdc.gov/agent/smallpox/training/overview/
 Redd SC; Kazembe PN; et al. Clinical algorithm for treatment of Plasmodium falciparum malaria in
children. AU Lancet 1996 Jan 27;347(8996):223-7.
 Hanson JP, Dondorp AM, Day NP. Malaria treatment in the United States.
JAMA. 2007 May 23;297(20):2264-77.
 Resolution WHA. 58.2. Malaria control. In: Fifty-eighth World Health Assembly, Resolutions and
Decisions Annex. Geneva: WHO; 2005. Available at:
http://www.who.int/gb/ebwha/pdf_files/WHA58/WHA58_2-en.pdf
 Global Partnership to Roll Back Malaria. The African Summit on Roll Back Malaria, Abuja, Nigeria, 25
April 2000. Geneva: WHO; 2000 (WHO/CDS/RBM/2000.17). Available at:
http://whqlibdoc.who.int/hq/2000/WHO_CDS_RBM_2000.17.pdf
 Matuschewski K, Mueller AK (2007). Vaccines against malaria - an update
FEBS Journal 274 (18), 4680–4687.
 Aponte JJ, Aide P, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a
highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial In Press,
Corrected Proof, Available online 18 October 2007
et al.
 VS Moorthy, MF Good and AVS Hill, Malaria vaccine developments, Lancet 363 (2004), pp. 150–156.
 Russell PF. Man’s Mastery of Malaria. London: Oxford University Press 1955.
 Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozoite-induced
falciparum malaria. Am J Med Sci 1973; 266: 169-77.
 SI Hay, CA Guerra, AJ Tatem, AM Noor and RW Snow, The global distribution and population at risk of
malaria: past, present and future, Lancet Infect Dis 4 (2004), pp. 327–336.
 Cohen S, McGregor GI & Carrington S (1961) Gamma-globulin and acquired immunity to human
malaria. Nature 192, 733–737.
 Sherman, IW. The Power of Plagues. ASM Press, Washington DC, 2006.
6129093.ppt plasmodium parasite zoology.

More Related Content

Similar to 6129093.ppt plasmodium parasite zoology.

Freeing the Americas from NIDs: Addressing the Unfinished Agenda
Freeing the Americas from NIDs: Addressing the Unfinished AgendaFreeing the Americas from NIDs: Addressing the Unfinished Agenda
Freeing the Americas from NIDs: Addressing the Unfinished AgendaKATIA DIAZ
 
Preventing infectious diseases florian and ciara
Preventing infectious diseases  florian and ciaraPreventing infectious diseases  florian and ciara
Preventing infectious diseases florian and ciaraacsanjali
 
Emerging and re emerging diseases
Emerging and re emerging diseasesEmerging and re emerging diseases
Emerging and re emerging diseasesSASMITANAYAK28
 
A shot in the Dark-Final
A shot in the Dark-FinalA shot in the Dark-Final
A shot in the Dark-FinalMichal Tal
 
michael-scognomillo-slide-presentation-powerpoint.pptx
michael-scognomillo-slide-presentation-powerpoint.pptxmichael-scognomillo-slide-presentation-powerpoint.pptx
michael-scognomillo-slide-presentation-powerpoint.pptxFaisalRafique27
 
Livestock and human health: The good, the bad, the gaps
Livestock and human health: The good, the bad, the gapsLivestock and human health: The good, the bad, the gaps
Livestock and human health: The good, the bad, the gapsILRI
 
Vaccines and diagnostics—The case for regional One Health centres of excellence
Vaccines and diagnostics—The case for regional One Health centres of excellence Vaccines and diagnostics—The case for regional One Health centres of excellence
Vaccines and diagnostics—The case for regional One Health centres of excellence ILRI
 
Bio303 Lecture 1 The Global Burden of Infection and an Old Enemy, Malaria
Bio303 Lecture 1 The Global Burden of Infection and an Old Enemy, MalariaBio303 Lecture 1 The Global Burden of Infection and an Old Enemy, Malaria
Bio303 Lecture 1 The Global Burden of Infection and an Old Enemy, MalariaMark Pallen
 
Antimalarial metabolization: what have we learnt so far?
Antimalarial metabolization: what have we learnt so far?Antimalarial metabolization: what have we learnt so far?
Antimalarial metabolization: what have we learnt so far?Premier Publishers
 
Knowledge of the Implementation of the Malaria Control Program in Four Health...
Knowledge of the Implementation of the Malaria Control Program in Four Health...Knowledge of the Implementation of the Malaria Control Program in Four Health...
Knowledge of the Implementation of the Malaria Control Program in Four Health...YogeshIJTSRD
 
MALARIA DAY - 25- APRIL- 2022.pptx
MALARIA DAY - 25- APRIL- 2022.pptxMALARIA DAY - 25- APRIL- 2022.pptx
MALARIA DAY - 25- APRIL- 2022.pptxAbhishekSamuel14
 
The context surrounding the emergence of infectious diseases and the need to ...
The context surrounding the emergence of infectious diseases and the need to ...The context surrounding the emergence of infectious diseases and the need to ...
The context surrounding the emergence of infectious diseases and the need to ...ILRI
 
krithiga malaria epid,lifecycle and prevention
krithiga malaria epid,lifecycle and preventionkrithiga malaria epid,lifecycle and prevention
krithiga malaria epid,lifecycle and preventionKrithiga Sivakumar
 
World health day theme for 2014- vector borne disease
World health day theme for 2014- vector borne diseaseWorld health day theme for 2014- vector borne disease
World health day theme for 2014- vector borne diseasePjs Sudhakar Naik
 
Global Public Health And Pandemics
Global Public Health And PandemicsGlobal Public Health And Pandemics
Global Public Health And Pandemicsrcard
 
Diseaese Eradication Past Present and Future
Diseaese Eradication Past Present and FutureDiseaese Eradication Past Present and Future
Diseaese Eradication Past Present and FutureEhab Omrani
 

Similar to 6129093.ppt plasmodium parasite zoology. (20)

Filaria 2018 modified
Filaria 2018 modifiedFilaria 2018 modified
Filaria 2018 modified
 
Freeing the Americas from NIDs: Addressing the Unfinished Agenda
Freeing the Americas from NIDs: Addressing the Unfinished AgendaFreeing the Americas from NIDs: Addressing the Unfinished Agenda
Freeing the Americas from NIDs: Addressing the Unfinished Agenda
 
Preventing infectious diseases florian and ciara
Preventing infectious diseases  florian and ciaraPreventing infectious diseases  florian and ciara
Preventing infectious diseases florian and ciara
 
Emerging and re emerging diseases
Emerging and re emerging diseasesEmerging and re emerging diseases
Emerging and re emerging diseases
 
A shot in the Dark-Final
A shot in the Dark-FinalA shot in the Dark-Final
A shot in the Dark-Final
 
Buss. ethic
Buss. ethicBuss. ethic
Buss. ethic
 
Antimalarial agents
Antimalarial agentsAntimalarial agents
Antimalarial agents
 
michael1.pptx
michael1.pptxmichael1.pptx
michael1.pptx
 
michael-scognomillo-slide-presentation-powerpoint.pptx
michael-scognomillo-slide-presentation-powerpoint.pptxmichael-scognomillo-slide-presentation-powerpoint.pptx
michael-scognomillo-slide-presentation-powerpoint.pptx
 
Livestock and human health: The good, the bad, the gaps
Livestock and human health: The good, the bad, the gapsLivestock and human health: The good, the bad, the gaps
Livestock and human health: The good, the bad, the gaps
 
Vaccines and diagnostics—The case for regional One Health centres of excellence
Vaccines and diagnostics—The case for regional One Health centres of excellence Vaccines and diagnostics—The case for regional One Health centres of excellence
Vaccines and diagnostics—The case for regional One Health centres of excellence
 
Bio303 Lecture 1 The Global Burden of Infection and an Old Enemy, Malaria
Bio303 Lecture 1 The Global Burden of Infection and an Old Enemy, MalariaBio303 Lecture 1 The Global Burden of Infection and an Old Enemy, Malaria
Bio303 Lecture 1 The Global Burden of Infection and an Old Enemy, Malaria
 
Antimalarial metabolization: what have we learnt so far?
Antimalarial metabolization: what have we learnt so far?Antimalarial metabolization: what have we learnt so far?
Antimalarial metabolization: what have we learnt so far?
 
Knowledge of the Implementation of the Malaria Control Program in Four Health...
Knowledge of the Implementation of the Malaria Control Program in Four Health...Knowledge of the Implementation of the Malaria Control Program in Four Health...
Knowledge of the Implementation of the Malaria Control Program in Four Health...
 
MALARIA DAY - 25- APRIL- 2022.pptx
MALARIA DAY - 25- APRIL- 2022.pptxMALARIA DAY - 25- APRIL- 2022.pptx
MALARIA DAY - 25- APRIL- 2022.pptx
 
The context surrounding the emergence of infectious diseases and the need to ...
The context surrounding the emergence of infectious diseases and the need to ...The context surrounding the emergence of infectious diseases and the need to ...
The context surrounding the emergence of infectious diseases and the need to ...
 
krithiga malaria epid,lifecycle and prevention
krithiga malaria epid,lifecycle and preventionkrithiga malaria epid,lifecycle and prevention
krithiga malaria epid,lifecycle and prevention
 
World health day theme for 2014- vector borne disease
World health day theme for 2014- vector borne diseaseWorld health day theme for 2014- vector borne disease
World health day theme for 2014- vector borne disease
 
Global Public Health And Pandemics
Global Public Health And PandemicsGlobal Public Health And Pandemics
Global Public Health And Pandemics
 
Diseaese Eradication Past Present and Future
Diseaese Eradication Past Present and FutureDiseaese Eradication Past Present and Future
Diseaese Eradication Past Present and Future
 

More from ssuser4d911a

6- Introduction to antibiotics .ppt treatment
6- Introduction to antibiotics .ppt treatment6- Introduction to antibiotics .ppt treatment
6- Introduction to antibiotics .ppt treatmentssuser4d911a
 
Healthy_Village_Facilitator_s_Guide-Malaria (4).pdf
Healthy_Village_Facilitator_s_Guide-Malaria (4).pdfHealthy_Village_Facilitator_s_Guide-Malaria (4).pdf
Healthy_Village_Facilitator_s_Guide-Malaria (4).pdfssuser4d911a
 
case3-malaria-170527190738 (1).pdf leishmania
case3-malaria-170527190738 (1).pdf leishmaniacase3-malaria-170527190738 (1).pdf leishmania
case3-malaria-170527190738 (1).pdf leishmaniassuser4d911a
 
malaria-180315092718.pdf parasitology zoology
malaria-180315092718.pdf parasitology zoologymalaria-180315092718.pdf parasitology zoology
malaria-180315092718.pdf parasitology zoologyssuser4d911a
 
plasmodiumspp-230727053539-5ffdb01.5.pdf
plasmodiumspp-230727053539-5ffdb01.5.pdfplasmodiumspp-230727053539-5ffdb01.5.pdf
plasmodiumspp-230727053539-5ffdb01.5.pdfssuser4d911a
 
leishmaniasisv2-170117152603.pdf parasitology
leishmaniasisv2-170117152603.pdf parasitologyleishmaniasisv2-170117152603.pdf parasitology
leishmaniasisv2-170117152603.pdf parasitologyssuser4d911a
 
23-HistopathologicalaspectsofCL.pdf leishmania
23-HistopathologicalaspectsofCL.pdf leishmania23-HistopathologicalaspectsofCL.pdf leishmania
23-HistopathologicalaspectsofCL.pdf leishmaniassuser4d911a
 
wahidspaper1.pdf leishmania major in libya
wahidspaper1.pdf leishmania major in libyawahidspaper1.pdf leishmania major in libya
wahidspaper1.pdf leishmania major in libyassuser4d911a
 
departmentofbiology-microsoftpowerpointpptx.pptx
departmentofbiology-microsoftpowerpointpptx.pptxdepartmentofbiology-microsoftpowerpointpptx.pptx
departmentofbiology-microsoftpowerpointpptx.pptxssuser4d911a
 
IntroZooNotes.ppt zoology ppt parasitology
IntroZooNotes.ppt zoology ppt parasitologyIntroZooNotes.ppt zoology ppt parasitology
IntroZooNotes.ppt zoology ppt parasitologyssuser4d911a
 
10397072.ppt parasitology zoology ppt malaria
10397072.ppt parasitology zoology ppt malaria10397072.ppt parasitology zoology ppt malaria
10397072.ppt parasitology zoology ppt malariassuser4d911a
 
Blood parasites (1).ppt parasitology zoology
Blood parasites (1).ppt parasitology zoologyBlood parasites (1).ppt parasitology zoology
Blood parasites (1).ppt parasitology zoologyssuser4d911a
 
10397072.ppt malaria parasitology zoology
10397072.ppt malaria parasitology zoology10397072.ppt malaria parasitology zoology
10397072.ppt malaria parasitology zoologyssuser4d911a
 
speakupafricaaccesssmcsbccandadvocacyfeb2017 (3).pptx
speakupafricaaccesssmcsbccandadvocacyfeb2017 (3).pptxspeakupafricaaccesssmcsbccandadvocacyfeb2017 (3).pptx
speakupafricaaccesssmcsbccandadvocacyfeb2017 (3).pptxssuser4d911a
 
10559480.ppt parasitology zoology ppt Aa
10559480.ppt parasitology zoology ppt Aa10559480.ppt parasitology zoology ppt Aa
10559480.ppt parasitology zoology ppt Aassuser4d911a
 
malariaprevention-180605135302.pptx parasitology
malariaprevention-180605135302.pptx parasitologymalariaprevention-180605135302.pptx parasitology
malariaprevention-180605135302.pptx parasitologyssuser4d911a
 
hemoflagellates trypanosomaibrahim 2017.pptx
hemoflagellates trypanosomaibrahim 2017.pptxhemoflagellates trypanosomaibrahim 2017.pptx
hemoflagellates trypanosomaibrahim 2017.pptxssuser4d911a
 
Bangladesh.ppt parasitology ( malaria parasite)
Bangladesh.ppt parasitology ( malaria parasite)Bangladesh.ppt parasitology ( malaria parasite)
Bangladesh.ppt parasitology ( malaria parasite)ssuser4d911a
 
10397072.ppt parasitology lucture zoology
10397072.ppt parasitology lucture zoology10397072.ppt parasitology lucture zoology
10397072.ppt parasitology lucture zoologyssuser4d911a
 
10397072.ppt parasitology lucture parasitology lucture
10397072.ppt parasitology lucture parasitology lucture10397072.ppt parasitology lucture parasitology lucture
10397072.ppt parasitology lucture parasitology lucturessuser4d911a
 

More from ssuser4d911a (20)

6- Introduction to antibiotics .ppt treatment
6- Introduction to antibiotics .ppt treatment6- Introduction to antibiotics .ppt treatment
6- Introduction to antibiotics .ppt treatment
 
Healthy_Village_Facilitator_s_Guide-Malaria (4).pdf
Healthy_Village_Facilitator_s_Guide-Malaria (4).pdfHealthy_Village_Facilitator_s_Guide-Malaria (4).pdf
Healthy_Village_Facilitator_s_Guide-Malaria (4).pdf
 
case3-malaria-170527190738 (1).pdf leishmania
case3-malaria-170527190738 (1).pdf leishmaniacase3-malaria-170527190738 (1).pdf leishmania
case3-malaria-170527190738 (1).pdf leishmania
 
malaria-180315092718.pdf parasitology zoology
malaria-180315092718.pdf parasitology zoologymalaria-180315092718.pdf parasitology zoology
malaria-180315092718.pdf parasitology zoology
 
plasmodiumspp-230727053539-5ffdb01.5.pdf
plasmodiumspp-230727053539-5ffdb01.5.pdfplasmodiumspp-230727053539-5ffdb01.5.pdf
plasmodiumspp-230727053539-5ffdb01.5.pdf
 
leishmaniasisv2-170117152603.pdf parasitology
leishmaniasisv2-170117152603.pdf parasitologyleishmaniasisv2-170117152603.pdf parasitology
leishmaniasisv2-170117152603.pdf parasitology
 
23-HistopathologicalaspectsofCL.pdf leishmania
23-HistopathologicalaspectsofCL.pdf leishmania23-HistopathologicalaspectsofCL.pdf leishmania
23-HistopathologicalaspectsofCL.pdf leishmania
 
wahidspaper1.pdf leishmania major in libya
wahidspaper1.pdf leishmania major in libyawahidspaper1.pdf leishmania major in libya
wahidspaper1.pdf leishmania major in libya
 
departmentofbiology-microsoftpowerpointpptx.pptx
departmentofbiology-microsoftpowerpointpptx.pptxdepartmentofbiology-microsoftpowerpointpptx.pptx
departmentofbiology-microsoftpowerpointpptx.pptx
 
IntroZooNotes.ppt zoology ppt parasitology
IntroZooNotes.ppt zoology ppt parasitologyIntroZooNotes.ppt zoology ppt parasitology
IntroZooNotes.ppt zoology ppt parasitology
 
10397072.ppt parasitology zoology ppt malaria
10397072.ppt parasitology zoology ppt malaria10397072.ppt parasitology zoology ppt malaria
10397072.ppt parasitology zoology ppt malaria
 
Blood parasites (1).ppt parasitology zoology
Blood parasites (1).ppt parasitology zoologyBlood parasites (1).ppt parasitology zoology
Blood parasites (1).ppt parasitology zoology
 
10397072.ppt malaria parasitology zoology
10397072.ppt malaria parasitology zoology10397072.ppt malaria parasitology zoology
10397072.ppt malaria parasitology zoology
 
speakupafricaaccesssmcsbccandadvocacyfeb2017 (3).pptx
speakupafricaaccesssmcsbccandadvocacyfeb2017 (3).pptxspeakupafricaaccesssmcsbccandadvocacyfeb2017 (3).pptx
speakupafricaaccesssmcsbccandadvocacyfeb2017 (3).pptx
 
10559480.ppt parasitology zoology ppt Aa
10559480.ppt parasitology zoology ppt Aa10559480.ppt parasitology zoology ppt Aa
10559480.ppt parasitology zoology ppt Aa
 
malariaprevention-180605135302.pptx parasitology
malariaprevention-180605135302.pptx parasitologymalariaprevention-180605135302.pptx parasitology
malariaprevention-180605135302.pptx parasitology
 
hemoflagellates trypanosomaibrahim 2017.pptx
hemoflagellates trypanosomaibrahim 2017.pptxhemoflagellates trypanosomaibrahim 2017.pptx
hemoflagellates trypanosomaibrahim 2017.pptx
 
Bangladesh.ppt parasitology ( malaria parasite)
Bangladesh.ppt parasitology ( malaria parasite)Bangladesh.ppt parasitology ( malaria parasite)
Bangladesh.ppt parasitology ( malaria parasite)
 
10397072.ppt parasitology lucture zoology
10397072.ppt parasitology lucture zoology10397072.ppt parasitology lucture zoology
10397072.ppt parasitology lucture zoology
 
10397072.ppt parasitology lucture parasitology lucture
10397072.ppt parasitology lucture parasitology lucture10397072.ppt parasitology lucture parasitology lucture
10397072.ppt parasitology lucture parasitology lucture
 

Recently uploaded

Hubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroidsHubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroidsSérgio Sacani
 
Boyles law module in the grade 10 science
Boyles law module in the grade 10 scienceBoyles law module in the grade 10 science
Boyles law module in the grade 10 sciencefloriejanemacaya1
 
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptxUnlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptxanandsmhk
 
Biopesticide (2).pptx .This slides helps to know the different types of biop...
Biopesticide (2).pptx  .This slides helps to know the different types of biop...Biopesticide (2).pptx  .This slides helps to know the different types of biop...
Biopesticide (2).pptx .This slides helps to know the different types of biop...RohitNehra6
 
BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.
BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.
BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.PraveenaKalaiselvan1
 
Genomic DNA And Complementary DNA Libraries construction.
Genomic DNA And Complementary DNA Libraries construction.Genomic DNA And Complementary DNA Libraries construction.
Genomic DNA And Complementary DNA Libraries construction.k64182334
 
Neurodevelopmental disorders according to the dsm 5 tr
Neurodevelopmental disorders according to the dsm 5 trNeurodevelopmental disorders according to the dsm 5 tr
Neurodevelopmental disorders according to the dsm 5 trssuser06f238
 
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.aasikanpl
 
A relative description on Sonoporation.pdf
A relative description on Sonoporation.pdfA relative description on Sonoporation.pdf
A relative description on Sonoporation.pdfnehabiju2046
 
Recombination DNA Technology (Microinjection)
Recombination DNA Technology (Microinjection)Recombination DNA Technology (Microinjection)
Recombination DNA Technology (Microinjection)Jshifa
 
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...jana861314
 
Orientation, design and principles of polyhouse
Orientation, design and principles of polyhouseOrientation, design and principles of polyhouse
Orientation, design and principles of polyhousejana861314
 
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...Sérgio Sacani
 
Grafana in space: Monitoring Japan's SLIM moon lander in real time
Grafana in space: Monitoring Japan's SLIM moon lander  in real timeGrafana in space: Monitoring Japan's SLIM moon lander  in real time
Grafana in space: Monitoring Japan's SLIM moon lander in real timeSatoshi NAKAHIRA
 
Nanoparticles synthesis and characterization​ ​
Nanoparticles synthesis and characterization​  ​Nanoparticles synthesis and characterization​  ​
Nanoparticles synthesis and characterization​ ​kaibalyasahoo82800
 
GFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxGFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxAleenaTreesaSaji
 
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...Sérgio Sacani
 
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptxSOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptxkessiyaTpeter
 
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxPhysiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxAArockiyaNisha
 

Recently uploaded (20)

Hubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroidsHubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroids
 
Boyles law module in the grade 10 science
Boyles law module in the grade 10 scienceBoyles law module in the grade 10 science
Boyles law module in the grade 10 science
 
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptxUnlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptx
 
Biopesticide (2).pptx .This slides helps to know the different types of biop...
Biopesticide (2).pptx  .This slides helps to know the different types of biop...Biopesticide (2).pptx  .This slides helps to know the different types of biop...
Biopesticide (2).pptx .This slides helps to know the different types of biop...
 
BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.
BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.
BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.
 
Genomic DNA And Complementary DNA Libraries construction.
Genomic DNA And Complementary DNA Libraries construction.Genomic DNA And Complementary DNA Libraries construction.
Genomic DNA And Complementary DNA Libraries construction.
 
Neurodevelopmental disorders according to the dsm 5 tr
Neurodevelopmental disorders according to the dsm 5 trNeurodevelopmental disorders according to the dsm 5 tr
Neurodevelopmental disorders according to the dsm 5 tr
 
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
 
A relative description on Sonoporation.pdf
A relative description on Sonoporation.pdfA relative description on Sonoporation.pdf
A relative description on Sonoporation.pdf
 
Recombination DNA Technology (Microinjection)
Recombination DNA Technology (Microinjection)Recombination DNA Technology (Microinjection)
Recombination DNA Technology (Microinjection)
 
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
 
Orientation, design and principles of polyhouse
Orientation, design and principles of polyhouseOrientation, design and principles of polyhouse
Orientation, design and principles of polyhouse
 
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
 
Grafana in space: Monitoring Japan's SLIM moon lander in real time
Grafana in space: Monitoring Japan's SLIM moon lander  in real timeGrafana in space: Monitoring Japan's SLIM moon lander  in real time
Grafana in space: Monitoring Japan's SLIM moon lander in real time
 
Nanoparticles synthesis and characterization​ ​
Nanoparticles synthesis and characterization​  ​Nanoparticles synthesis and characterization​  ​
Nanoparticles synthesis and characterization​ ​
 
GFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxGFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptx
 
The Philosophy of Science
The Philosophy of ScienceThe Philosophy of Science
The Philosophy of Science
 
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
 
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptxSOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
 
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxPhysiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
 

6129093.ppt plasmodium parasite zoology.

  • 2. “What is the most repeated failure in all of global health? It could well be the commitment to eradicate malaria.” Bill Gates, October 17,2007
  • 3. 45 minutes from now you will know all of this:  Malaria epidemiology  A historical perspective on malaria  Some romantic malaria-themed poetry to use on your next date  Clinical manifestations and diagnosis  Basics of treatment  Malaria at DUMC  Global eradication efforts  Why the VA Jets will win the Turkey Bowl this year
  • 4. What is malaria?  Malaria is a vector-borne disease caused by protozoa: – P. falciparum – P. vivax – P. ovale – P. malariae – P. knowlesi
  • 5. Worldwide Distribution SI Hay, CA Guerra, AJ Tatem, AM Noor and RW Snow, The global distribution and population at risk of malaria: past, present and future, Lancet Infect Dis 4 (2004), pp. 327–336.
  • 7. Malaria Epidemiology  300-500 million cases per year worldwide  700,000 to 2.7 million deaths per year  ~1300 cases in the US reported to the CDC in 2004  Average 2 cases per year at DUMC
  • 8. Malaria in Antiquity  Genetic analysis has suggested that a virulent Plasmodia falciparum evolved 6000 years ago (“Malaria’s Eve”) around the time of the emergence of agricultural societies  However it appears that some populations are 50,000 to 400,000 years old  ie, older than homo sapiens  
  • 9. Malaria in antiquity  Enlarged spleen, periodic fevers, headaches, and chills are described in the Ebers papyrus (~1550 BC) as well as in ancient Chinese medical texts www.wikipedia.org
  • 10. Nobel Prizes for work on malaria  1902 – Ronald Ross  1907 – Charles Louis Alphonse Laveran – discovered that malaria is caused by a protozoan  1927 – Julius Wagner-Juaregg – for his discovery of the therapeutic value of malaria inoculation in the treatment of dementia paralytica (caused by neurosyphilis)  1948 - Paul Hermann Müller – For his discovery of the high efficiency of DDT as a contact poison against several arthropods
  • 11. Ronald Ross  Scottish physician, mathematician, poet, playwright, writer, and painter  Bombay 1895 – recruited volunteers to drink water with dead mosquitoes  caused fever but not parasitemia  Switched tactics to having mosquitoes bite infected patients then dissecting the mosquitoes, but was using Culex and Aedes instead of Anopheles until 1897 http://en.wikipedia.org/wiki/Ronald_ross
  • 12. This day relenting God Hath placed within my hand A wondrous thing: and God Be praised. At his command Seeking his secret deeds With tears and toiling breath, I find thy cunning seeds O million-murdering death I know this little thing A myriad men will save. O death, where is thy sting? Thy victory, O grave?
  • 14. Clinical Manifestations  FEVER  HA, myalgia, N/V/D, abdominal pain, cough, diarrhea  Anemia, thrombocytopenia, splenomegaly, jaundice – hepatomegaly uncommon  Cerebral malaria with P. falciparum – AMS, seizures, coma – more common in kids
  • 15. Diagnosis  In Malawi: mother’s report of fever in her child – 93% sensitive, 21% specific  Missionary algorithm: fever and/or diarrhea  treat for malaria for three days  if no better, treat for typhoid for three days  if no better, think  T>37.6 + nail pallor + splenomegaly – 85% sensitive, 41% specific  Thick/thin smear – remains the standard
  • 16. Diagnosis  Thick smear: one drop of blood on a slide, spread to area 1cm2 – RBCs hemolyzed, parasites and leukocytes detectable – Used to detect and quantify parasitemia  Thin smear: fixed with methanol  no hemolysis – Used to identify species
  • 18. Malaria at DUMC  Consider malaria in any febrile patient who has been to a malaria-endemic area in the year prior to presentation – In the 2007 JAMA review, 98% of patients with P. falciparum in the US became symptomatic within 3 months of arrival to the US – 96% of patients with non-falciparum malaria became symptomatic within 12 months
  • 19. Malaria drugs  Quinoline derivatives – inhibit heme polymerase  accumulate free heme which is toxic to the parasites – chloroquine, quinine, quinidine, amodiaquine, mefloquine, halofantrine, primaquine  Artemisinin derivatives – bind iron in malarial pigment  form free radicals toxic to the parasites – Artemisinin, artemether, artesunate – Not available in the US – Clinical resistance has not been documented
  • 20. Malaria drugs (cont.)  Antifolates – pyrimethamine, sulfonamides, dapsone, proguanil  Antimicrobials – clindamycin, atovaquone, tetracyclines – synergistic with quinolines – active against blood schizonts
  • 21. Global Eradication Efforts  WHO in 1955 set a goal to eradicate malaria  The US was heavily invested, behind the support of Eisenhower, George Marshall, and JFK "I propose that the United States join with other nations and organizations which are already spending over $50 million a year on anti- malaria activities. In five years, these activities are expected to eradicate this disease." - Eisenhower, addressing Congress in 1953
  • 22. Global Eradication Efforts – The First Attempt  Efforts were largely based on DDT and chloroquine, which was successful for a time – But insecticide-resistant mosquitoes evolved, and chloroquine-resistant parasites – And there was that issue with fragile eggshells  Funding decreased after the failure of the campaign in the 1950’s and 1960’s
  • 23. Global Eradication Efforts – The Resurgence  The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) – an independent public-private partnership formed in 2002 – was first proposed by the UN Secretary- General, Kofi Annan – Approx 1/3 of the money is donated by the US
  • 24. Global Eradication Efforts – The Resurgence  President’s Malaria Initiative (2005) – Pledge to increase funding by the US by at least $1.2 billion over five years – Joins USAID, DHHS, CDC, Dept of State – Goal is to provide prevention and treatment measures to 85% of children under 5 and pregnant women
  • 25. Global Eradication Efforts – The Resurgence  Roll Back Malaria Partnership – Formed in 1998 by WHO, UNICEF, UNDP, World Bank – Aims for coverage of:  60% of children and pregnant women with ITNs  60% of malaria cases receive effective therapy within 24 hours  60% of pregnant women receive intermittent presumptive therapy  60% of epidemics be detected within two weeks of onset and responded to within 2 more weeks
  • 26. Global Eradication Efforts – The Resurgence  World Bank’s “Rolling Back Malaria: The Global Strategy and Booster Program“ – Emphasizes the economic cost of malaria (close to 1% of sub-Saharan Africa’s GDP) and the cost-effectiveness of control (eg $2,762 per life saved for a program in Brazil) http://siteresources.worldbank.org/INTMALARIA/Resources/377501- 1114188195065/execsum.pdf
  • 27. Global Eradication Efforts  WHO in 2005 asked members to set a target of 50% reduction in malaria burden by 2010 and 75% by 2015  Melinda Gates, October 17, 2007: “… the rising concern of people around the world represents an historic opportunity not just to treat malaria or to control it—but to chart a long- term course to eradicate it.”
  • 28.  Bill and Melinda Gates Foundation – $7.8 billion in grants dispersed from inception to March 2007 (not all for malaria) – Projects have included:  successful ITN coverage in Zambia  funding the RTS/S vaccine trial in Mozambique
  • 29.  Current funding is about $2 billion per year – $1 billion donor money – $600 million from endemic countries and their citizens – $400 million R&D
  • 30.  2006 Sports Illustrated column established a program to distribute insecticide-treated nets (nothingbutnets.com)
  • 31.  “I teach you to lie, cheat, and steal, and as soon as my back is turned you wait in line? Get an MRI and get a better medical history”  “If a human being had actually looked at his blood, anywhere along the way, instead of just running tests through the computer, parasites would have jumped right out at them.“  “Patients sometimes get better. You have no idea why, but unless you give a reason they won't pay you.”
  • 33. The Backlash “Chronic disease is already the biggest problem for poor and middle-income countries. To concentrate so much on infections is to add to the health burden of the next generation in what are already the world's poorest, unhealthiest places.” -The Economist, 8/9/07
  • 34. Strategies For Malaria Control  Vector control – eg. insecticides  Exposure prophylaxis – eg. bednets  Clinical management – better drugs, better access  Vaccines
  • 35. Malaria vaccine  Basic reproductive number R0 for an infection  – R0 = mean # of new cases a single infected case will cause in a population with no immunity and in the absence of interventions to control the infection  If R0 < 1 then the infection will not persist in a population  R0 > 1 then epidemics can occur  1 – 1/R0 is the proportion of the population that needs to be vaccinated to provide herd immunity (prevent sustained spread)
  • 36. Herd Immunity Thresholds for Selected Vaccine-Preventable Diseases Immunization Levels Disease Ro Herd Immunity 1999 19-35 Months 1997-1998 Pre-School Diphtheria 6-7 85%* 83%* 9% Measles 12-18 83-94% 92% 96% Mumps 4-7 75-86% 92% 97% Pertussis 12-17 92-94% 83%* 97% Polio 5-7 80-86% 90% 97% Rubella 6-7 83-85% 92% 97% Smallpox 5-7 80-85% __ __ *4 doses † Modified from Epid Rev 1993;15: 265-302, Am J Prev Med 2001; 20 (4S): 88-153, MMWR 2000; 49 (SS-9); 27-38
  • 37.  The R0 for malaria in Africa is estimated at 50-100  Therefore to eliminate endemic malaria would require 99% coverage with a lifelong vaccine (that is 100% effective) at 3 months of age
  • 38. Malaria Vaccine  The first human malaria vaccine was reported in 1973 – but used the bites of thousands of mosquitoes infected with irradiated plasmodia  Current efforts have two broad strategies – subunit vaccines that mimic naturally acquired immunity – experimental model vaccines, eg live attenuated parasites and transmission-blocking antigens
  • 39. Malaria Vaccine  SPf66 was the first vaccine to undergo field trials after promising phase I trials, but was not more effective than placebo in larger trials  There are currently at least 25 candidate vaccines in development, of which RTS,S/AS02A is the furthest along
  • 40. Malaria Vaccine  Double-blind RCT of 214 children in Mozambique who received RTS,S/AS02D or Hep B vaccine at 10 weeks, 14 weeks, and 18 weeks of age  Vaccine is made of 2 falciparum surface proteins (RTS and S fused to HbsAg)  Primary endpoint was safety at 6 months  Secondary endpoint was vaccine efficacy at 3 months – which was 65% (5% of children who got the malaria vaccine vs 8% of the controls)
  • 41. Summary  Consider malaria in any febrile patient with recent travel to an endemic area  Get a thick and thin smear  Poetry about malaria is actually not very romantic  Although the malaria epidemic continues largely unabated, there is growing political and financial will to push for eradication
  • 42.
  • 43. “ I hope you will judge yourselves not on your professional accomplishments alone, but also on how well you have addressed the world’s deepest inequities… on how well you treated people a world away who have nothing in common with you but their humanity.” - Bill Gates June 7, 2007
  • 44. References  Joy DA, Feng X, et al. Early Origin and recent expansion of Plasmodium falciparum. Science; 2003 Apr 11;300(5617):318-21.  Singh B, Kim Sung L, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 2004 Mar 27;363(9414):1017-24.  Anderson RM, May RM. "Population biology of infectious diseases: Part I". Nature 280 (5721): 361-7.  CDC: http://www.bt.cdc.gov/agent/smallpox/training/overview/  Redd SC; Kazembe PN; et al. Clinical algorithm for treatment of Plasmodium falciparum malaria in children. AU Lancet 1996 Jan 27;347(8996):223-7.  Hanson JP, Dondorp AM, Day NP. Malaria treatment in the United States. JAMA. 2007 May 23;297(20):2264-77.  Resolution WHA. 58.2. Malaria control. In: Fifty-eighth World Health Assembly, Resolutions and Decisions Annex. Geneva: WHO; 2005. Available at: http://www.who.int/gb/ebwha/pdf_files/WHA58/WHA58_2-en.pdf  Global Partnership to Roll Back Malaria. The African Summit on Roll Back Malaria, Abuja, Nigeria, 25 April 2000. Geneva: WHO; 2000 (WHO/CDS/RBM/2000.17). Available at: http://whqlibdoc.who.int/hq/2000/WHO_CDS_RBM_2000.17.pdf
  • 45.  Matuschewski K, Mueller AK (2007). Vaccines against malaria - an update FEBS Journal 274 (18), 4680–4687.  Aponte JJ, Aide P, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial In Press, Corrected Proof, Available online 18 October 2007 et al.  VS Moorthy, MF Good and AVS Hill, Malaria vaccine developments, Lancet 363 (2004), pp. 150–156.  Russell PF. Man’s Mastery of Malaria. London: Oxford University Press 1955.  Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 1973; 266: 169-77.  SI Hay, CA Guerra, AJ Tatem, AM Noor and RW Snow, The global distribution and population at risk of malaria: past, present and future, Lancet Infect Dis 4 (2004), pp. 327–336.  Cohen S, McGregor GI & Carrington S (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192, 733–737.  Sherman, IW. The Power of Plagues. ASM Press, Washington DC, 2006.